ALKemist Bio

ALKemist Bio is a biotechnology company based in Turin, Italy, founded in 2023.

The company focuses on developing T-cell-based immunotherapies specifically for ALK-positive cancers, including treatment-resistant tumors like lymphoma, neuroblastoma, and non-small cell lung cancer. Their innovative platform involves engineering autologous T cells with synthetic receptors, utilizing CAR and TCR approaches to target the ALK oncogene and effectively eliminate cancer cells. ALKemist Bio offers a pipeline of cellular immunotherapies, particularly TCR-T cell therapies aimed at ALK antigens. Their work emphasizes precision immunology and T-cell engineering, with the goal of enhancing safety, overcoming resistance, and extending remission for patients with ALK-positive cancers. The company is committed to serving the oncology and biopharma ecosystem, focusing on improving outcomes for patients affected by these specific tumors.